Common Contracts
31 similar Employment Agreement contracts by IDEAYA Biosciences, Inc., Gritstone Oncology, Inc., Eargo, Inc., others
IDEAYA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 10th, 2023 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (the “Agreement”) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Andres Ruiz Briseno (“Executive” and, together with the Company, the “Parties”) effective as of July 1, 2023 (the “Effective Date”). This Agreement supersedes in its entirety that certain Employment Agreement between Executive and the Company dated as of November 1, 2021 (“Prior Agreement”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • March 7th, 2023 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Darrin Beaupre, M.D., PhD (“Executive” and, together with the Company, the “Parties”) effective as of November 21, 2022 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2022 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New Jersey
This Employment Agreement (the “Agreement”), is entered into effective as of December 7, 2020 (the “Effective Date”), by and between Mereo BioPharma Group plc, a company incorporated in England and Wales (the “Company”) and Suba Krishnan (“Executive” and, together with the Company, the “Parties”).
PARAGON 28, INC. EMPLOYMENT AGREEMENTEmployment Agreement • October 8th, 2021 • Paragon 28, Inc. • Surgical & medical instruments & apparatus • Colorado
This Employment Agreement (the “Agreement”), entered into as of October 8, 2021 (the “Effective Date”), is between Paragon 28, Inc., a Delaware corporation (the “Company”) and Matthew Jarboe (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain employment offer letter agreement between Executive and the Company dated as of January 1, 2020 (“Offer Letter”).
PARAGON 28, INC. EMPLOYMENT AGREEMENTEmployment Agreement • October 8th, 2021 • Paragon 28, Inc. • Surgical & medical instruments & apparatus • Colorado
This Employment Agreement (the “Agreement”), entered into as of October 8, 2021 (the “Effective Date”), is between Paragon 28, Inc., a Delaware corporation (the “Company”) and Stephen M. Deitsch (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain employment offer letter agreement between Executive and the Company dated as of September 28, 2020 (“Offer Letter”).
PARAGON 28, INC. EMPLOYMENT AGREEMENTEmployment Agreement • October 8th, 2021 • Paragon 28, Inc. • Surgical & medical instruments & apparatus • Colorado
This Employment Agreement (the “Agreement”), entered into as of October 8, 2021 (the “Effective Date”), is between Paragon 28, Inc., a Delaware corporation (the “Company”) and Albert DaCosta (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain employment offer letter agreement between Executive and the Company dated as of January 1, 2020 (“Offer Letter”).
AMPLITUDE, INC. EMPLOYMENT AGREEMENTEmployment Agreement • August 30th, 2021 • Amplitude, Inc. • Services-prepackaged software • California
This Employment Agreement (the “Agreement”), entered into as of [ ], 20[ ] (the “Effective Date”), is between Amplitude, Inc., a Delaware corporation (the “Company”) and [ ] (“Executive” and, together with the Company, the “Parties”). [This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of [ ] (“Offer Letter”).]
EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2021 • Mereo Biopharma Group PLC • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), is entered into effective as of July 1, 2020 (the “Effective Date”), by and between Mereo BioPharma Group plc, a company incorporated in England and Wales (the “Company”) and John Lewicki, Ph.D. (“Executive” and, together with the Company, the “Parties”).
IDEAYA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 23rd, 2021 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Jason S. Throne (“Executive” and, together with the Company, the “Parties”) effective as of February 24, 2021 (the “Effective Date”). This Agreement supersedes in its entirety that certain Employment Agreement between Executive and the Company dated as of October 9, 2019 (“Prior Agreement”)
EARGO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 25th, 2020 • Eargo, Inc. • Orthopedic, prosthetic & surgical appliances & supplies • California
This Employment Agreement (the “Agreement”), dated September 25, 2020, is between Eargo, Inc., a Delaware corporation (the “Company”) and Adam Laponis (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the closing of the initial public offering of the Company’s common stock (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of May 8, 2019 (“Offer Letter”) effective as of the Effective Date.
EARGO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 25th, 2020 • Eargo, Inc. • Orthopedic, prosthetic & surgical appliances & supplies • California
This Employment Agreement (the “Agreement”), dated September 25, 2020, is between Eargo, Inc., a Delaware corporation (the “Company”) and Christian Gormsen (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the closing of the initial public offering of the Company’s common stock (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of February 17, 2016 (“Offer Letter”) effective as of the Effective Date.
EARGO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 25th, 2020 • Eargo, Inc. • Orthopedic, prosthetic & surgical appliances & supplies • California
This Employment Agreement (the “Agreement”), dated September 25, 2020, is between Eargo, Inc., a Delaware corporation (the “Company”) and William Brownie (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the closing of the initial public offering of the Company’s common stock (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of August 18, 2016 (“Offer Letter”) effective as of the Effective Date.
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • March 24th, 2020 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is entered into between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Jason S. Throne (“Executive” and, together with the Company, the “Parties”) effective as of October 9, 2019 (the “Effective Date”).
REVOLUTION MEDICINES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into effective as of December 18, 2019 (the “Effective Date”), is between Revolution Medicines, Inc., a Delaware corporation (the “Company”) and Margaret Horn (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of November 9, 2014 (“Offer Letter”).
REVOLUTION MEDICINES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into effective as of December 18, 2019 (the “Effective Date”), is between Revolution Medicines, Inc., a Delaware corporation (the “Company”) and Mark Goldsmith (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of October 29, 2014 (“Offer Letter”).
REVOLUTION MEDICINES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • January 17th, 2020 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into effective as of December 18, 2019 (the “Effective Date”), is between Revolution Medicines, Inc., a Delaware corporation (the “Company”) and Steve Kelsey (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of January 23, 2017 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 17th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May 9, 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Paul A. Stone (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of February 13, 2018 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 17th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May 15, 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Jeffrey Hager (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of October 28, 2015 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 17th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May 10, 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Mark R. Lackner, Ph.D. (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of May 1, 2018 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 17th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May 9, 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Julie Hambleton, M.D. (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of February 20, 2018 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 17th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May 10, 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Michael Dillon, Ph.D. (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of February 13, 2016 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 13th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May 9, 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and Yujiro Hata (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of October 29, 2015 (“Offer Letter”).
IDEAYA BIOSCIENCES, INC. FORM OF EXECUTIVE EMPLOYMENT AGREEMENTEmployment Agreement • May 13th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), entered into as of May [ ], 2019, is between IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”) and [ ] (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of May 1, 2018 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Roman Yelensky (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of September 22, 2015 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Raphaël Rousseau (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of November 15, 2016 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Erin Jones (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of March 23, 2016 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018(the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Andrew Allen (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of October 7, 2015 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Jayant Aphale (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of February 9, 2018 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Jean-Marc Bellemin (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of December 16, 2017 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Karin Jooss (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of February 29, 2016 (“Offer Letter”).
GRITSTONE ONCOLOGY, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 17th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”), entered into as of September 16, 2018 (the “Agreement Date”), is between Gritstone Oncology, Inc., a Delaware corporation (the “Company”) and Matthew Hawryluk (“Executive” and, together with the Company, the “Parties”). This Agreement will become effective as a binding contract as of the Agreement Date, but the operative provisions of this Agreement will only become effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of October 8, 2015 (“Offer Letter”).
